MX2016014359A - Antigeno e de hepadnavirus marcado y su uso en el tamizado de sustancias antivirales. - Google Patents

Antigeno e de hepadnavirus marcado y su uso en el tamizado de sustancias antivirales.

Info

Publication number
MX2016014359A
MX2016014359A MX2016014359A MX2016014359A MX2016014359A MX 2016014359 A MX2016014359 A MX 2016014359A MX 2016014359 A MX2016014359 A MX 2016014359A MX 2016014359 A MX2016014359 A MX 2016014359A MX 2016014359 A MX2016014359 A MX 2016014359A
Authority
MX
Mexico
Prior art keywords
antigen
hepadnavirus
tagged hepadnavirus
methods
substances
Prior art date
Application number
MX2016014359A
Other languages
English (en)
Inventor
Guo Haitao
Ji Changhua
Cai Dawei
Cuconati Andrea
Original Assignee
Univ Drexel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Drexel filed Critical Univ Drexel
Publication of MX2016014359A publication Critical patent/MX2016014359A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/42—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a HA(hemagglutinin)-tag
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/005—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination repressible enhancer/promoter combination, e.g. KRAB
    • C12N2830/006—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination repressible enhancer/promoter combination, e.g. KRAB tet repressible
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/02—Hepadnaviridae, e.g. hepatitis B virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a métodos y usos para el tamizado de sustancias anti-hepadnavirales, en donde las sustancias son tamizadas para detectar la capacidad para inhibir ADN circular covalentemente cerrado (ccc) de un hepadnavirus, tal como virus de la hepatitis B. Los métodos y usos toman ventaja de células que comprenden una secuencia de ácido nucleico que codifica para un antígeno e de hepadnavirus marcado, tal como antígeno e de virus de la hepatitis B (HBeAg). Además, la presente invención proporciona secuencias de ácido nucleico que codifican paran un antígeno e de hepadnavirus marcado y proteínas codificadas por las mismas. También se proporcionan kits para uso en los métodos de tamizado.
MX2016014359A 2014-06-20 2015-06-19 Antigeno e de hepadnavirus marcado y su uso en el tamizado de sustancias antivirales. MX2016014359A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462014996P 2014-06-20 2014-06-20
PCT/EP2015/063838 WO2015193484A1 (en) 2014-06-20 2015-06-19 Tagged hepadnavirus e antigen and its use in screening antiviral substances

Publications (1)

Publication Number Publication Date
MX2016014359A true MX2016014359A (es) 2017-06-12

Family

ID=53498969

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016014359A MX2016014359A (es) 2014-06-20 2015-06-19 Antigeno e de hepadnavirus marcado y su uso en el tamizado de sustancias antivirales.

Country Status (10)

Country Link
US (2) US10072047B2 (es)
EP (2) EP3521303A1 (es)
JP (1) JP6543338B2 (es)
KR (1) KR102309355B1 (es)
CN (1) CN106716128B (es)
BR (1) BR112016024458A2 (es)
CA (1) CA2943047C (es)
MX (1) MX2016014359A (es)
RU (1) RU2711750C2 (es)
WO (1) WO2015193484A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108611395A (zh) * 2016-12-12 2018-10-02 中山大学 一种抗人乙肝病毒药物的筛选方法
CN107022543A (zh) * 2017-05-25 2017-08-08 郑州市第六人民医院 一种提取乙型肝炎病毒核酸用磁珠、提取试剂、提取方法、定量检测用试剂盒
WO2020072207A1 (en) * 2018-10-04 2020-04-09 The Rockefeller University Rna-based methods to launch hepatitis b virus infection
EP4022072A4 (en) * 2019-08-29 2023-09-06 G Tech Bio LLC COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS
CN113832169A (zh) * 2020-06-24 2021-12-24 厦门大学 靶向HBV cccDNA的药物筛选模型及方法
CN113293179A (zh) * 2021-05-10 2021-08-24 武汉科技大学 一种靶向敲除HBx蛋白的质粒及其构建方法和应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5491084A (en) 1993-09-10 1996-02-13 The Trustees Of Columbia University In The City Of New York Uses of green-fluorescent protein
CN101104867A (zh) * 2006-07-10 2008-01-16 中国人民解放军第四军医大学 检测乙型肝炎病毒cccDNA的巢式-实时定量PCR方法
CA2874828A1 (en) 2012-06-01 2013-12-05 Drexel University Modulation of hepatitis b virus cccdna transcription

Also Published As

Publication number Publication date
WO2015193484A1 (en) 2015-12-23
US10214567B2 (en) 2019-02-26
RU2016152429A (ru) 2018-07-23
KR20170068411A (ko) 2017-06-19
CN106716128A (zh) 2017-05-24
CN106716128B (zh) 2020-06-23
BR112016024458A2 (pt) 2017-10-10
KR102309355B1 (ko) 2021-10-06
RU2711750C2 (ru) 2020-01-21
EP3157944B1 (en) 2019-10-09
US20170240600A1 (en) 2017-08-24
JP2017518081A (ja) 2017-07-06
JP6543338B2 (ja) 2019-07-10
EP3157944A1 (en) 2017-04-26
CA2943047A1 (en) 2015-12-23
US10072047B2 (en) 2018-09-11
RU2016152429A3 (es) 2019-02-27
CA2943047C (en) 2023-03-14
US20180312546A1 (en) 2018-11-01
EP3521303A1 (en) 2019-08-07

Similar Documents

Publication Publication Date Title
MX2016014359A (es) Antigeno e de hepadnavirus marcado y su uso en el tamizado de sustancias antivirales.
CY1121934T1 (el) Αντισωματα anti-fcrn
EA201690529A1 (ru) Способы модификации клетки-хозяина
EA201590488A1 (ru) Способы модификации клеток-хозяев
MX2016016904A (es) Analisis de secuencias de acidos nucleicos.
CR20210084A (es) Receptores quiméricos y métodos de uso de los mismos (divisional 2018-0480)
MX2023005262A (es) Composiciones y metodos relacionados con particulas depuradoras.
MX2019002498A (es) Metodos y productos para la expresion de proteinas en celulas.
SG10201903822XA (en) Method for the enrichment of circulating tumor dna
WO2015109124A3 (en) Immunomodulatory agents
WO2014200910A3 (en) Bioinformatic processes for determination of peptide binding
MX2021000210A (es) Metodos y productos para transfeccion de celulas.
BR112016016916A2 (pt) método de tratamento de angiodema hereditário (hae)
MX2017001403A (es) Constructo de anticuerpo de cadena individual biespecifico con distribucion mejorada de tejido.
MX2016016886A (es) Anticuerpos anti-axl.
CY1121964T1 (el) Αντισωματα εναντιον toy csf-1r
EA201890611A1 (ru) Библиотеки модульных полипептидов и способы их получения и применения
CY1122214T1 (el) Αντισωματα ειδικα για ton fcrn
MX2017014397A (es) Anticuerpos anti-receptor neonatal de fragmento cristalizable(fcrn).
EA201892774A1 (ru) Антитела
SG10201909180SA (en) Humanized anti-c1s antibodies and methods of use thereof
EA201791610A1 (ru) Проникающие в клетку антитела
SG10201807572PA (en) Robust antibody purification
MX2021001418A (es) Produccion de proteinas heteromultimericas usando celulas de mamifero.
PH12017500722A1 (en) Antibodies that potently neutralize rabies virus and other lyssaviruses and uses thereof

Legal Events

Date Code Title Description
FG Grant or registration